8-K filing — Bluejay Diagnostics, Inc. (BJDX)
Filed: 2026-09-08 AccNo: 0001213900-26-098071 Size: 443 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Bluejay Diagnostics And Lovell Announce Distribution, Co-Marketing And Strategic Partnership To Support Introduction Of Bluejay’s Products Into U.S. Federal Healthcare Market
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bluejay Diagnostics shares are trading higher after the company announced a strategic partnership with Lovell Government Services to support the introduction of its products into the federal healthcare market.
Bluejay Diagnostics Q2 EPS $(1.12) Up From $(5.64) YoY
Bluejay Diagnostics (NASDAQ:BJDX) reported quarterly losses of $(1.12) per share. This is a 80.14 percent increase over losses of $(5.64) per share from the same period last year.